No profile data available.
ArriVent BioPharma, Inc. (AVBP) is a healthcare company in the additional cancer treatment drugs industry, based in Newtown Square, United States, with about 77 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$166.31 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $824.92 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
ArriVent BioPharma reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$824.92 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Adlai Nortye Ltd. (ANL), Cullinan Therapeutics, Inc. (CGEM), Replimune Group, Inc. (REPL), Candel Therapeutics, Inc. (CADL).